Jens Van Fraeyenhove

Jens Van Fraeyenhove

Auto-generated profile, based on publicly available information

Jens Van Fraeyenhove

Laboratory of Physiopharmacology, GENCOR, University of Antwerp, Antwerp, Belgium; Consortium of Excellence Infla-Med, University of Antwerp, Antwerp Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
EFEline Feyen
Eline Feyen
MRMelanie Ricke-Hoch
Melanie Ricke-Hoch
JFJens Van Fraeyenhove
Jens Van Fraeyenhove
ZVZarha Vermeulen
Zarha Vermeulen
MSMichaela Scherr
Michaela Scherr
GKGilles W. De Keulenaer
Gilles W. De Keulenaer
Background: Peripartum cardiomyopathy (PPCM) is a life-threatening disease in women without previously known cardiovascular disease. It is characterized by a sudden onset of heart failure before or after delivery. Previous studies revealed that the generation of a 16-kDa PRL (prolactin) metabolite, the subsequent upregulation of miR-146a, and the downregulation of the target gene Erbb4 is a common driving factor of PPCM. Methods: miRNA profiling was performed in plasma of PPCM patients (n=33) and postpartum-matched healthy CTRLs (controls; n=36). Elevated miRNAs in PPCM plasma, potentially targeting ERBB4 (erythroblastic leukemia viral oncogene homolog 4), were overexpressed in cardiomyocytes using lentiviral vectors. Next, cardiac function, cardiac morphology, and PPCM phenotype were investigated after recurrent pregnancies of HZ (heterozygous) cardiomyocyte-specific Erbb4 mice ( Erbb4 F/+ αMHC-Cre + , n=9) with their age-matched nonpregnant CTRLs (n=9–10). Results: Here, we identify 9 additional highly conserved miRNAs (miR-199a-5p and miR-199a-3p, miR-145a-5p, miR-130a-3p, miR-135a-5p, miR-221-3p, miR-222-3p, miR-23a-3p, and miR19b-3p) that target tyrosine kinase receptor ERBB4 and are over 4-fold upregulated in plasma of PPCM patients at the time of diagnosis. We confirmed that miR-146a, miR-199a-5p, miR-221-3p, miR-222-3p, miR-23a-3p, miR-130a-5p, and miR-135-3p overexpression decreases ERBB4 expression in cardiomyocytes (−29% to −50%; P <0.05). In addition, we demonstrate that genetic cardiomyocyte-specific downregulation of Erbb4 during pregnancy suffices to induce a variant of PPCM in mice, characterized by left ventricular dilatation (postpartum second delivery: left ventricular internal diameter in diastole, +19±7% versus HZ-CTRL; P <0.05), increased atrial natriuretic peptide (ANP) levels (4-fold increase versus HZ-CTRL mice, P <0.001), decreased VEGF (vascular endothelial growth factor) and VE-cadherin levels (−33±17%, P =0.07; −27±20%, P <0.05 versus HZ-CTRL), and histologically enlarged cardiomyocytes (+20±21%, versus HZ-CTRL, P <0.05) but without signs of myocardial apoptosis and inflammation. Conclusions: ERBB4 is essential to protect the maternal heart from peripartum stress. Downregulation of ERBB4 in cardiomyocytes induced by multiple miRNAs in the peripartum period may be crucial in PPCM pathophysiology. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00998556.

4 October 2025 in Current Opinion in Pharmacology
Verified
Journal Article
Open access
JFJens Van Fraeyenhove
Jens Van Fraeyenhove
GGGiulia Guerra
Giulia Guerra
EHEmilio Hirsch
Emilio Hirsch
AGAlessandra Ghigo
Alessandra Ghigo
Doxorubicin (DOX) remains a cornerstone in the treatment of various malignancies, but its clinical use is limited by cardiotoxicity, a leading cause of heart failure in cancer survivors. While oxidative stress and direct myocardial injury have long been implicated in DOX-induced cardiotoxicity (DIC), emerging evidence highlights the central role of immune dysregulation in disease progression. In particular, neutrophils, macrophages, and T cells orchestrate inflammatory responses that contribute to cardiomyocyte injury, adverse remodeling, and fibrosis. Recent findings also point to novel mediators that may serve as biomarkers or therapeutic targets. This review synthesizes current evidence on immune mechanisms underlying DIC and discusses how improved understanding of these pathways may inform immunomodulatory strategies to reduce cardiac injury without compromising anticancer efficacy.

5 May 2026 in Heart Rhythm
Verified
Journal Article
Closed access
JFJens Van Fraeyenhove
Jens Van Fraeyenhove
MTMichiel R.L. Tubeeckx
Michiel R.L. Tubeeckx
BGBo Goovaerts
Bo Goovaerts
YFYile Fu
Yile Fu
JZJuan Zhang
Juan Zhang
GKGilles W. De Keulenaer
Gilles W. De Keulenaer